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models, and represents those where cost is the main determinant of outcomes. The 
latter includes the more developed Shanghai model which encompasses a more 
holistic approach with consideration for the quality, patent status and degree of 
innovation of a medicine. Analysis of published tender results shows a significant 
variation between the resultant prices in different provinces, with as much as 50% 
difference between the tender price and MRP set by the NDRC. Price erosion is 
greatest for generic medicines and those where a larger degree of competition 
exists, indicating that market forces ultimately have the greatest effect on tendering 
outcomes. ConClusions: Our results demonstrate the large degree of variation 
between tendering processes in China. Although “price focused” models typically 
result in high downwards pricing pressure, “quality focused” models are more recep-
tive of innovative medicines, thus, achieving price premiums is possible.
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objeCtives: To study the Regulatory reforms and its impact on Clinical Trials in 
India. The present study involves the lacune in conducting Clinical Trials and pre-
sents the Regulatory reforms in India. Methods: India is an emerging destination 
for Clinical Research because of its genetic pool, availability of patients for enrol-
ment, infrastructure and talented pool of physicians. In order to ensure patient 
safety in Clinical Trials several regulatory reforms have been implemented by the 
ministry of health and family welfare, Govt. of India. These include constitution of 
ethics committee’s, audio video recording of the consent, audit and inspections of 
the sites, registration of ethics committee’s etc. Compensation policy for deaths dur-
ing the clinical trials have been framed. In order to ensure patient safety, National 
Pharmacovigilance Programme of India (PvPI) have been launched in the country 
for the safety monitoring of drugs as a post marketing surveillance. PvPI is work-
ing in coordination with the WHO Uppsala Monitoring Centre. The presentation 
will discuss the salient regulatory reforms for patient’s safety in clinical research 
in India. Results: In order to ensure the safety of patients, the reporting culture 
of the Adverse Drug Reactions have been improved. There is a pool of 70000 ADR’S 
in the PvPI database and number of ADR Centres have been increased to 150 in 
various parts of the country. With the implementation of new Regulatory reforms, 
there is tranparency in the system. Culture of Reporting ADR’S by the physicians 
have also increased. The Ethical Review Boards have been prooperly strengthened, 
Serious Adverse Drug Reactions are being reported to the regulatory agency and 
compensations are being paid in the Clinical Trials. ConClusions: It is concluded 
that the new Regulatory Reforms will ensure the safety of the patients during the 
Clinical Trials.
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objeCtives: To describe the drug utilization pattern in the treatment of patients 
with septic shock in the ICU. Methods: Setting: 7-bed mixed medical/surgical 
intensive care unit (ICU) of a tertiary care teaching hospital. A retrospective cohort 
study of patients with septic shock, who were treated in the ICU between January 
2012 and December, 2013. The ICU database was used to identify the patients. The 
patient demographics and characteristics were recorded. In addition, the number 
and type of prescribed medications, type of infection, and culture results were deter-
mined. The main outcomes were the type of medication classes utilized and their 
comparison between the survivors & non-survivors. Results: During the study 
period, 109 cases were identified. Upon presentation, the mean Acute Physiology 
and Chronic Health Evaluation II (APACHE II) score was 22.5 (SD ±7.8), 93 (85.3 %) 
patients had leucocytosis, and 84 (77.0 %) had positive cultures. The mean num-
ber of medications prescribed per patient was 11.7 (SD ±4.7). The most commonly 
prescribed medication classes were proton pump inhibitors, carbapenems, BL/BLI 
combinations and vasopressors prescribed in 101 (92.6 %), 75 (68.8 %), 64 (58.7 %), and 
91 (83.4 %) patients, respectively. Antifungals and blood products were prescribed 
in 45 (41.2 %) and 77 (70.6 %) patients, respectively. Medication usage were higher 
in non-survivors, compared to survivors (12.6 ± 2.4 versus 9.7±4.1), and in patients 
with positive cultures (13.5±1.9 versus 9.3± 3.6) compared to patients with negative 
cultures. ConClusions: In patients with severe sepsis and septic shock, multiple 
medications were prescribed, and the use of medications was higher in the non-
survivors in comparison to the survivors.
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objeCtives: Jos loss has been shown to negatively affect displaced workers’ 
health. But it remains unclear how job loss affects medication use and spending 
on prescription drugs. The purpose of this study was to examine the impact of job 
loss on the use of medications as measured by out-of-pocket payment for the last 
prescription. Methods: A quasi-experimental design was used to study workers 
who did and did not experience involuntary job displacement. The data was drawn 
from four waves of the Medical Expenditure Panel Survey (MEPS), taken in 2008, 
2009, 2010, and 2011. Involuntary job loss was defined as job separation due to 
“job ended” or “business dissolved or sold”. Our analysis was limited to adults who 
participated in all five rounds of interviews. Results: While the average out-of-
pocket payment for the last prescription remained unchanged for those remained 
employed (around $23.10), the spending for those lost job increased by $2.82 ($19.41 
vs. $22.23). Compared with those who remained employed, those who experienced 
to 71.45% because of unfair competition between pharmaceutical distribution 
companies and cooperation failure between pharmaceutical manufacturers and 
pharmaceutical suppliers. ConClusions: Successful pharmaceutical supply sys-
tem of essential medicines needs to clearly define the function and to coordinate 
competition and cooperation relationship between pharmaceutical manufacturers, 
distribution companies and township hospitals. KeywoRds: essential medicine; 
availability; organizational arrangement.
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objeCtives: There have been several strict cost containment measures, as refer-
ence pricing system and global budget, being aplied in Turkish health care system 
especially for drugs. As a result of these measures; most of the drugs being marketed 
in Turkey have the lowest price in Europe. In this regard, several drugs including 
the drugs being used in critical diseases such as cancer, orphan diseases etc, have 
been withdrawn from the market or even they wouldn’t be able to enter the market. 
Therefore, Turkish government brings these drugs from abroad by paying much 
more money compared to the current or the future prices (the price if the drug 
would have licenced or being reimbursed) of those drugs in Turkey. The aim of this 
study is to analyze the list of these drugs according to their ATC groups. Methods: 
The list of Social Security Institution (SSI) on drugs bringing from abroad (Annex 4 
C) have been analyzed in assistance with RxMediaPharma® Program. Results: In 
total, there are 662 drugs being listed in the latest Annex 4-C list. Among this list; 
the most frequently listed ATC group is L (antineoplastic and immunomodulating 
agents) by 22%, second is A (alimentary tract and metabolism) by 13.3%, third is C 
(cardiovascular system) by 12.5%, fourth and fifth are; N (nervous system) by 12% 
and J (antiinfectives for systemic use) by 6,35% relatively. ConClusions: Strict 
cost containment measures being applied in Turkey causes shortages of several 
drugs especially the ones being used in diseases with high mortality rates like 
cancer. In this situation, despite government has brought these medicines from 
abroad, as this procedure takes some time, patients may have trouble in reaching 
these drugs on time and SSI pays much more for these drugs compared to their 
probable prices in Turkey.
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objeCtives: Pharmacoeconomics and outcomes research (PEOR) has emerged as 
a key decision-making tool to optimize patient care and add value to health care 
services. Considering the strategic importance of Asian markets and economic con-
straints in the pharmaceutical sector, an understanding of current pricing strategies 
become vital for market authorization holders as well as payers. Methods: An 
assessment of health care policies, pricing systems, and reforms impacting reim-
bursement and market access environment was undertaken across major Asian 
markets (Japan, China, South Korea, and India). Information sources included online 
portals of regulatory agencies and relevant keyword searches. Results: Health 
policy decisions over recent years have indicated varying levels of priorities and 
interests within Asia. Japan continues to increase health care investments and 
attempts are being made to expedite drug approval process. Despite a robust pricing 
mechanism, Japanese pharmacoeconomic guidelines are yet to be implemented. 
Public health expenditure in China has witnessed almost 50% growth since 2004. 
Chinese pharmacoeconomic guidelines are now in practice and pricing norms 
have gained more structure with the introduction of external referencing and price 
negotiations with drug companies. In South Korea, pharmacoeconomic guidelines 
are well-established and the current focus is on cost-containment measures like 
profit controls and price cuts. Pharmacoeconomics in India is still in its nascent 
stage but the 2013 Drugs (Prices Control) Order (DPCO) included radical changes 
focussing on market-based pricing. Furthermore, the introduction of price negotia-
tion mechanisms is also being considered by the Department of Pharmaceuticals 
(DoP) in India. ConClusions: The focus on PEOR by reimbursement agencies in the 
West has compelled their Asian counterparts to revisit pricing policies. Japan has 
started drafting pharmacoeconomic guidelines, while Chinese and South Korean 
governments have implemented new mechanisms to manage drug prices. In India, 
the DoP has encouraged revisions in the DPCO and further reforms in pricing mecha-
nisms are expected in the near future.
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objeCtives: In China, maximum retail prices of reimbursed medicines are con-
trolled at the national level by the National Development and Reform Commission 
(NDRC). At the provincial level, different tendering processes are used to procure 
medicines, often resulting in disparity between provinces and a significantly lower 
final price than the MRP. The objective of this research is to understand the dif-
ferent provincial tendering models and evaluate the resultant effect on medi-
cine prices. Methods: We conducted secondary research of both national and 
provincial government websites to identify the different tendering models used 
across China. Provincial tender results were analyzed to understand the final 
price variation between provinces, relative to the MRP. Finally, primary research 
was conducted with payers in provinces with well-established tendering models - 
including Anhui, Beijing, Fujian, Hebei and Shanghai - to understand the individual 
nuances. Results: Tendering models exist on a continuum between “price focused” 
and “quality focused” processes. The former includes both the Anhui and Fujian 
